DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Desmopressin Acetate 0.2 mg Tablets, Fasting

Information source: Teva Pharmaceuticals USA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Desmopressin Acetate 0.2 mg Tablets (Drug); DDAVP® 0.2 mg Tablets (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Teva Pharmaceuticals USA

Official(s) and/or principal investigator(s):
Gaetano Morelli, M.D., Principal Investigator, Affiliation: MDS Pharma Services

Summary

The objective of this study was to compare the single-dose relative bioavailability of TEVA and Aventis Pharmaceuticals (DDAVP®) 0. 2 mg desmopressin acetate tablets following a 0. 8 mg dose under fasting conditions.

Clinical Details

Official title: Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg Desmopressin Acetate Tablets in Healthy Adult Subjects Following a 0.8 mg Dose Under Fasting Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome:

Cmax - Maximum Observed Concentration

AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

Detailed description: Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA bioequivalence statistical methods

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy adult non-smoker (for at least 3 months) or light smoking (less than 10

cigarettes per day for at least 3 months) male or female subjects, 18-55 years of age;

- Weighing at least 60 kg for males and 52 kg for females;

- Subjects who had a body mass index (BMI) less than 30;

- Medically healthy subjects with clinically normal laboratory profiles and ECGs;

Females of childbearing potential should have either been sexually inactive (abstinent) for 14 days prior to the first dose and throughout the study or have been using one of the following acceptable birth control methods:

- surgically sterile (tubal ligation, hysterectomy, bilateral oophorectomy) 6 months

minimum. Proof was required for the hysterectomy and oophorectomy;

- IUD in place for at least 3 months;

- barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the

first dose and throughout the study;

- surgical sterilization of the partner (vasectomy for 6 months minimum);

- hormonal contraceptives for at least 3 months prior to the first dose of the study.

Other birth control methods were deemed acceptable. Postmenopausal women with amenorrhea for at least 2 years were eligible.

- Voluntarily consent to participate in the study.

Exclusion Criteria:

- Female subjects who were pregnant or lactating.

- Subjects who had been on a special diet (for whatever reason) during the 28 days

prior to the first dose and throughout the study.

- Any clinically significant illness within 4 weeks prior to dosing.

- Subjects with any medical condition requiring regular treatment with prescription

drugs.

- The use of any pharmacological agents known to significantly induce or inhibit

drug-metabolizing enzymes within 30 days prior to the first dose.

- Subjects who, through completion of the study, would have donated in excess of: 500

mL of blood and/or plasma in 14 days; 1500 mL of blood and/or plasma in 180 days; 2500 mL of blood and/or plasma in 1 year.

- Subjects who had donated plasma within 30 days prior to the first dose.

- Subjects who ahd participated in another clinical trial within 30 days prior to the

first dose.

- Subjects who did not tolerate venipuncture.

- History or presence of significant cardiovascular, pulmonary, hepatic, renal,

hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease. In addition, the history or presence of:

- hypersensitivity or idiosyncratic reaction to desmopressin or any other synthetic

anti-diuretic hormones;

- type IIB von Willebrand's disease;

- personal or family bleeding disorder;

- alcoholism or drug abuse within the past year.

Locations and Contacts

MDS Pharma Sercives, St. Laurent, Quebec H4R 2N6, Canada
Additional Information

Starting date: July 2003
Last updated: September 1, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017